ClinicalTrials.gg

Program

BL-M09D1

Its studies are mostly in Carcinoma, Transitional Cell · Carcinoma, Non-Small-Cell Lung · Digestive System Neoplasms, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 2, since Aug 12, 20264 company-led studies, 4 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical44 open or runningphase 2since Aug 12, 2026Apr 24, 2025May 2027phase 1 · NCT06954077

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2025First study: phase 1 study in Digestive System NeoplasmsFirst studyNCT06954077 · 45 planned · China
  2. Jun 30, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07056556 · 31 planned · China
  3. Aug 12, 2026Phase 2 study in Gynecological MalignanciesPhase 2 reachedNCT07769229 · 126 planned · China
  4. Sep 18, 2026Phase 2 study in Carcinoma, Transitional CellNCT07837622 · 42 planned · China

Ahead

  1. May 2027Primary completion: phase 1 study in Digestive System NeoplasmsNCT06954077
  2. Dec 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07056556
  3. Dec 2028Primary completion: phase 2 study in Carcinoma, Transitional CellNCT07837622
  4. Dec 2028Primary completion: phase 2 study in Gynecological MalignanciesNCT07769229

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07837622Carcinoma, Transitional Cell · China2Not yet recruitingDec 202842
NCT07769229Gynecological Malignancies · China2Not yet recruitingDec 2028126
NCT07056556Carcinoma, Non-Small-Cell Lung · China1RecruitingDec 202731
NCT06954077Digestive System Neoplasms · China1RecruitingMay 202745

How it is read

Names in the registry

  • “BL-M09D1”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.